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Background: Omeprazole preparations vary in bioavailability in horses.
Hypothesis/Objectives: To characterize the pharmacokinetics and pharmacodynam-
ics of an existing enteric-coated oral omeprazole paste (REF) and a novel, in-feed,
enteric-coated dry granule preparation (NOV).
Animals: Twelve Standardbred/Thoroughbred mares free from clinical disease.
Methods: A prospective, blinded randomized interventional study was trial, con-
ducted in 3 parts: (a) bioavailability study, (b) dose titration study, and (c) comparative
clinical pharmacodynamic study, each using a blocked crossover design.
Results: Consistent with the larger dose administered, Cmax (median, 1032 ng/mL;
range, 576-1766) and AUC0-24 (median, 63.9 μg/mL*min; range, 42.4-152.4) were
greater after single oral administration of NOV than REF (282.7 ng/mL; range,
94.8-390.2, and 319 23.8 μg/mL*min; range, 8.2-42.3, respectively; both P = .004).
No differences were observed between products for absolute oral bioavailability
(NOV 55% range, 15-88; REF 17% range, 10-77; P = .25). Treatment with both prep-
arations was associated with reduced gastric squamous ulcer scores and increased
pH of gastric fluid. Bioequivalence was demonstrated for pharmacodynamic mea-
sures with the exception of % time pH <4, despite differences in dose rate and subse-
quent plasma omeprazole concentrations.
Conclusions and Clinical Importance: The findings of this study indicate that the
NOV product would be a suitable alternative to the reference product, and confirm
that plasma concentrations of omeprazole and omeprazole dose do not predict drug
pharmacodynamics in horses.
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1 | INTRODUCTION
Equine gastric ulcer syndrome (EGUS) is the most common abnormal-
ity of the equine stomach1 and has been associated with colic,
decreased appetite, failure to thrive, and poor performance.2-5 Equine
squamous gastric disease (ESGD) is the most recognized form of
EGUS. Gastric ulcers in this portion of the stomach are likely caused
by exposure to organic acids, including hydrochloric acid, volatile fatty
acids, and bile acids.6-8 Treatment of ESGD is affected primarily by
sustained increase in the pH of gastric fluid, thereby limiting the expo-
sure of the squamous mucosa to acidic contents.7,9-12
Omeprazole is a substituted benzimidazole that is effective for
the suppression of gastric acid secretion in horses by inhibition of the
H+/K+ ATPase enzyme system at the secretory surface of gastric pari-
etal cells.13,14 This effect of omeprazole is dose related and leads to
inhibition of both basal and stimulated acid secretion.13,14
Plasma concentrations of omeprazole can vary considerably and
be unpredictable after oral administration.13,15 Although the drug has
a short elimination half-life, absorption after oral administration might
be protracted, and absorption, rather than clearance (Cl), is the major
determinant of drug concentration.16 Omeprazole is acid labile and
bioavailability of the drug is improved by administration of buffered
formulations or by enteric coating,16 and by withholding feed before
administration.13,17 To date, enteric-coated preparation of omeprazole
for administration to horses are suspensions of granules administered
in a paste. Although omeprazole is cleared rapidly from plasma, secre-
tion of gastric acid is reduced until resynthesis of H+ pumps in the
parietal cell membranes occurs. Plasma omeprazole concentration,
therefore, does not necessarily predict gastric pH, and further studies
are required to characterize the pharmacokinetic (PK) and pharmaco-
dynamic (PD) effects of omeprazole in horses.
The objectives of this study were to further characterize the PK and
PD of omeprazole in horses by comparative studies of an existing enteric-
coated oral paste preparation and a novel, in-feed, enteric-coated dry
granule preparation. We hypothesized that the PD effects of omeprazole,
administered PO, would be dose-dependent, and that bioavailability of
the drug would be reduced by in-feed administration of the novel prod-
uct, impacting the bioequivalence of the 2 omeprazole products. We fur-
ther hypothesized that plasma concentrations of omeprazole, and the
effect of treatment on gastric pH, would be greater after repeated admin-
istration, as described for other oral omeprazole preparations.18,19
2 | METHODS AND MATERIALS
2.1 | Subjects
Horses used in this study were Standardbred and Thoroughbred
mares (Supplementary Item 1) from the Charles Sturt University
teaching herd. All horses were free from clinical disease, based on
physical, hematological, and blood biochemical examinations, and had
not been administered any medications within 4 weeks of the start of
the study. Throughout the study, feed was withheld from horses for
10 hours before the administration of the assigned product, and medi-
cation was dosed according to body weight. Horses were weighed
within 24 hours of the first day of treatment in each part of the study,
and every 7 days when stabled, using calibrated scales. Horses were
accommodated in stables during each study. Physical examination
was performed daily, and fecal output, food, and water consumption
were monitored twice daily for all horses when stabled. Horses were
maintained at pasture when not stabled for withholding of feed, accli-
matization/washout or treatment.
2.2 | Administration of medication
Three omeprazole products were used in the study; an omeprazole prepa-
ration for IV administration (Omeprazole Sandoz IV 40 mg; Sandoz Pty
Ltd Macquarie Park, Australia), an existing enteric-coated oral paste refer-
ence (REF) preparation (Gastrozol Daily Oral Paste for Horses; 50 mg/mL:
Virbac Australia Pty Ltd, Milperra, Australia; APVMA product number
58757) and a novel (NOV), in-feed, enteric-coated dry granule preparation
(Equestra Omeprazole Granules: 250 mg/g: Equestra, Wodonga, Victoria,
Australia; APVMA product number 87882).
Omeprazole was administered IV into the jugular vein using a
21G, 38 mm needle to ensure that the full dose was administered;
blood samples after IV administration of drug were collected from
catheters placed in the contralateral jugular vein. The commercial
omeprazole paste (REF) was administered by placing the dosing
syringe into the mouth through the lateral commissure of the lips,
ensuring the entire dose was delivered and retained within the mouth.
The assigned dose of the novel omeprazole product (NOV) was
offered for free choice consumption in 20.0 g of bran. The calculated
dose of omeprazole granules, and bran feed, were weighed using sci-
entific scales, and omeprazole granules were mixed by hand to ensure
even distribution of granules. Consumption of the entire dose was
documented by the research assistant administering the medication,
and the time taken to consume the entire dose was recorded.
2.3 | Study design
The study was conducted as a prospective, randomized, interventional
study in 3 parts (Supplementary Item 1): (a) a bioavailability study
comparing oral absorption of both products, (b) a dose titration study
after administration of NOV at 2 dose rates, and (c) a comparative
pharmacodynamics study. All parts of this study had approval from
the animal care and ethics committee at “masked for review”: Part
1, Approval number A17074; Part 2, Approval number A17043; Part
3, Approval number A17076).
2.3.1 | Part 1: Bioavailability study
The bioavailability study included 9 horses and was conducted as a
3 sequence, 3 period Latin square design, with horses randomly
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assigned to each sequence. Three horses were randomly allocated
(by ballot) to each of the 3 treatment sequences, before period
1. Plasma concentrations of omeprazole were determined after
administration of a single oral dose of REF (1 mg/kg) or NOV
(2 mg/kg), in comparison with the IV administration of omeprazole
(0.5 mg/kg). Venous blood samples were collected from jugular cathe-
ters into heparinized vacutainers for determination of plasma omepra-
zole concentrations, before treatment and at 1, 5, 10, 15, 30, 45,
60, 75, 90, 105, 120, and 150 minutes and 3, 4, 5, 6, 8, 12, and
24 hours after administration of omeprazole. Samples were placed on
ice, and the plasma was separated within 2 hours of collection and
stored at −20C before analysis. There was at least a 5 day washout
between each period.
2.3.2 | Part 2: Dose titration study
The dose titration study included 8 horses and was conducted as a
blinded, randomized, blocked, 2 treatment (NOV 2 mg/kg or 4 mg/kg,
in 20 g of bran), 2 period cross-over study. Initial gastroscopy and
24 hours gastric pH determination were performed in untreated
horses. Horses were blocked into 2 groups of 4, with 2 horses in each
block randomly assigned (by ballot) to receive NOV 2 mg/kg in 20 g
of bran, and 2 horses to receive NOV 4 mg/kg in 20 g of bran. Horses
were then housed in a paddock for 8 to 14 days before commence-
ment of treatment period 1. After being returned to the paddock for a
13-day washout, each horse received the alternative dose in treat-
ment period 2. Gastroscopy and 24-hour gastric pH determination
were performed after administration of the assigned single oral omep-
razole dose in treatment periods 1 and 2.
2.3.3 | Part 3: Comparative clinical PD study
Comparative pharmacodynamics of REF and NOV were assessed in
12 horses in a blinded, randomized, 2 treatment (REF 1 mg/kg PO
q24h for 7 days, NOV 2 mg/kg PO q24h for 7 days), 2 period,
2 sequence trial with sequential cross over. Horses were blocked into
groups of 4, with 2 horses in each block randomly allocated (by ballot)
to NOV treatment, and 2 horses allocated to REF treatment.
All horses underwent a 14 day acclimatization period before
administration of medication and a 14 day washout period between
treatment periods. Gastroscopy and 24 hour measurement of
intragastric pH was performed in untreated horses on day 7 of the
acclimatization and washout periods. Pharmacokinetic data were
assessed by determination of plasma concentrations of omeprazole
from samples collected before treatment and 15, 30, 45, 60, 75, 90,
and 120 minutes and 3, 4, 5, 6, 7, 8, 12, and 24 hours on day 0, after
administration of the first allocated treatment, and on day 5, after
administration of the penultimate treatment. Pharmacodynamic data
and treatment efficacy were assessed by determination of gastric
squamous ulcer scores and 24 hour gastric pH on treatment days
1 and 6, after administration of treatment. Sampling for PK and PD
analysis was performed on separate days because gastroscopy and
nasogastric tube (NGT) placement required sedation, and this was
considered likely to affect gastric emptying or drug metabolism.
Horses were treated as previously described, except that horses
receiving REF were also fed 20.0 g of bran immediately after treat-
ment, to ensure consistency between the treatment of horses with
the 2 omeprazole preparations.
2.4 | Gastroscopy and gastric fluid pH
determination
Horses underwent gastroscopy before the administration of treatment in
parts 2 and 3. Before the procedure, horses were stabled and feed was
withheld for a minimum of 10 hours and were sedated by IV administra-
tion of 200 mg xylazine (Xylazil-100, TROY Laboratories Pty Ltd,
Glendenning, New South Wales, Australia) and 10 mg acepromazine
(Acepril-10, TROY Laboratories Pty Ltd). When gastroscopy was per-
formed before the administration of omeprazole, medication was adminis-
tered 60 to 120 minutes after sedation. Endoscopy was performed using
a 3 m endoscope (Olympus Medical Systems Corporation, Tokyo, Japan).
Visualization of the mucosa was optimized by insufflation with air until
gastric rugae were absent. Mucosa was rinsed of adherent food material
with water flushed through the endoscope biopsy channel. Squamous
ulceration was assessed using a published grading scale20,21 by an
observer blinded to treatment (SLR). Gastroscopic examinations were
identified using a unique 4 digit random number, and each examination
was video recorded for blinded, de-identified analysis, if required.
Continuous gastric pH determination was performed for 24 hours
as previously described20 using a modified antimony pH electrode
(Synectics customized multi-use 1 channel antimony pH electrode,
external reference; diameter 2.1 mm, length 300 cm; product number
MMS810100; MD Solutions Pty Ltd, Williamstown North, Victoria,
Australia) coupled to a data logger (Orion II Ambulatory pH Recorder,
Medial Measurement Systems [MMS], MD Solutions Pty Ltd). The
probe was placed within an indwelling NGT (Mila Veterinary Enteral
Feeding Tube, 18 French x 250 cm; product number NG18100, Mila
International, Erlanger, Kentucky) which was placed via endoscopic
guidance, as previously described.20 Probe placement within the gas-
tric fluid was confirmed before endoscope removal, and the tube was
sutured to the external nares. Gastric pH was recorded by the data
logger at 1 second intervals. The NGT and pH probes were removed
after 24 hours of recording time and data were imported from the
data logger onto a personal computer using commercially available
software (Medical Management Systems database software; Version
9.5, February 23, 2017; http://ww.mmsinternational.com/) and
graphs of pH over time, including periods of pH <4 were created to
visually assess pH profiles. The mean pH and % time pH <4 were cal-
culated using Microsoft Excel (Microsoft Office Professional Plus
2013, 15.0.5215.1000) after excluding pH readings <0.8 or >10 from
analysis, as these results corresponded to loss of contact with gastric
fluid on inspection of traces. Probes damaged or displaced within
12 hours of placement were replaced. Unless damaged during
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recording or removal, probe accuracy was verified at the time of
removal by placing the probe in calibration fluids of pH 7, 4, and 1 and
results were discarded if not within 0.5 units of the pH standard or
verified by ex vivo determination of pH of aspirated fluid, as described
below.
Gastric fluid was aspirated endoscopically before placement of
the pH electrode and upon removal of the electrode. When possible,
gastric fluid was aspirated via the indwelling NGT every 60 to
120 minutes for 16 hours after NGT placement. The pH of the aspi-
rated fluid was determined by a bench top pH meter (220 Portable
pH/mV Meter; Instrument Choice, trading as Synotronics Pty Ltd,
Regency Park, South Australia, Australia) within 2 hours of collection.
The pH meter was calibrated and verified against standard solution of
pH 7, 4, and 1 before sample analysis, with verification repeated after
every 5 to 6 samples to ensure pH readings were within ±0.1 of
expected pH for each standard solution. Assessment of gastric pH
was based on data from both the probe and the aspirated gastric fluid
sampled, with the lowest recorded value used for analysis.
2.5 | Plasma omeprazole analysis
Omeprazole concentrations in plasma were determined by ultra-high
performance liquid chromatography tandem mass spectrometry
(UPLC-MS/MS) based on assays previously described.20 In brief,
analysis was performed using a Waters Acquity H-class UPLC sys-
tem (Waters Corporation, Milford, Massachusetts) coupled to a
Waters Xevo triple quadrupole mass spectrometer (Waters
F IGURE 1 Plasma omeprazole
concentration after IV administration of
omeprazole (0.5 mg/kg) and oral
administration of a commercially available
omeprazole product (REF, 1 mg/kg) and a
novel in-feed omeprazole product (NOV,
2 mg/kg), after single (day 0) (top) and
repeated (day 5) administration of NOV
and REF (bottom). Results are shown as
mean and 95% confidence interval
WISE ET AL. 623
Corporation), and Aquity BEH C18 UPLC column (Waters Corpora-
tion; 2.1 × 100 mm × 1.7 μm). The UPLC was operated with a
mobile phase consisting of 0.1% (v/v) formic acid (Solvent A) and
acetonitrile (Solvent B). Analyses were undertaken using multiple
reaction monitoring in positive electrospray ionization mode. Assay
performance was assessed by determining accuracy and precision
using standards (each n = 6) at low (10 ng/mL), moderate (300 ng/
mL), and high 1500 (ng/mL) concentrations. Linearity was estimated
in triplicate using calibration standards containing 0, 2, 10, 50,
200, 1000, and 5000 ng/mL omeprazole in equine plasma with
20 ng D3-omeprazole added to a 100 μL aliquot of each standard.
Standards were processed and analyzed, as described above, on
each of 3 different days. Lower limit of quantification (LLoQ) and
method detection limit (MDL) were determined by the signal to
noise (S/N) ratio of a 0.2 ng/mL standard with LLoQ determined at
S/N = 10 and MDL at S/N = 3. Matrix suppression was determined
using drug-free equine plasma which was precipitated with 4 vol-
umes of methanol/acetone (1:1). In a separate set of vials, omepra-
zole standard at moderate (n = 4) and high (n = 4) concentrations
was added and the solvent was evaporated. These omeprazole stan-
dards were reconstituted with either 60% acetonitrile or with
plasma-derived matrix in 60% acetonitrile before UHPLC-MS/MS
analysis to determine the level of ion suppression produced by the
plasma matrix by comparison ion counts. Dilution integrity was
determined using a standard sample at the upper limit of quantita-
tion (5000 ng/mL) in plasma diluted by a factor of 2 using drug-free
plasma (n = 6) and also by a factor of 4 (n = 6). The diluted samples
were analyzed for omeprazole, and accuracy and precision were
determined to assess dilution integrity.
The absence of analyte response in drug-free plasma
(F Selectivity) was assessed using drug-free plasma obtained from
6 different equine subjects, extracted and analyzed for peak area
corresponding to omeprazole and D3-omeprazole. Carry over was
determined after an initial injection of 5000 ng/mL omeprazole,
followed by 2 blank injections (methanol alone).
2.6 | Pharmacokinetics




where area under the curve (AUC0-t) is the area under the plasma
drug concentration-time (0-24 hours) curve and D is the dose
administered. The relative bioavailability of both oral omeprazole
products was calculated on results from bioavailability and bio-
equivalence studies, as previously described,21 normalized for the
different doses (REF 1 mg/kg, NOV 2 mg/kg) and assuming that
drug Cl was equal for both preparations. Maximum plasma omep-
razole concentration (Cmax) and time to Cmax (Tmax) were deter-
mined directly from data. Area under the curve (AUC0-t) and area
under the first moment curve (AUMC0-∞) were calculated using
the linear trapezoidal rule, and the terminal elimination rate con-
stant (λz) was calculated from the terminal phase of the log-linear
drug-concentration time curve using PK Solver22 ensuring at least
5 data points were included. Remaining PK parameters, including
terminal volume of distribution (Vz), initial volume of distribution
(Vd), steady state volume of distribution (Vss), half-life (t1/2), Cl and
mean residence time (MRT) were calculated using accepted
methods (Supplementary Item 2).
F IGURE 2 Gastric pH in untreated horses (baseline, dashed line), and after administration of omeprazole granules (NOV) at 2 mg/kg (green)
and 4 mg/kg (red). Data are shown as mean and SEM. Time had an effect on gastric pH (P = .003), whereas there was no difference between
treatments (P = .12) or an interaction between time and treatment (P = .46). Within each treatment, differences in comparison to pretreatment
values are shown (**P = .005; *P < .05). Results from untreated horses were not different at any time point. Values obtained between 0100 and
0600 hours (shaded gray) were derived from gastric pH probe only (not compared with results from aspirated gastric fluid), and were excluded
from statistical comparisons. Horses were treated at 0800 hours and fed at 1000 and 1800 hours (arrows)
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2.7 | Statistical analyses
Sample size calculations, based on previous results,20 indicated that
8 horses would discriminate a difference in gastric pH of 1.4 with
power of 0.8 and α of 0.05, assuming a standard deviation of 1. Data
were tested for normality using the Shapiro-Wilk test and for outliers
using Grubb's method. Outliers were retained in reporting descriptive
data and in comparative analyses. Pharmacokinetic parameters were
compared by Wilcoxon matched-pairs signed rank test. Log gastric pH
was assessed by restricted maximum likelihood mixed-effects model
with time and treatment as fixed factors, and horse as a random
factor, with post hoc testing by Tukey method. Model assumptions
(checked before analyses) were that residuals were normally dis-
tributed, had constant variance and were independent. Summary
statistics (initial pH, % time pH <4 and AUC pH-time) were evalu-
ated by 1-way repeated measures ANOVA, or ANOVA on ranks
using the Friedman test for nonparametric data, with post hoc
pairwise comparisons by Tukey or Dunn's test, respectively. Signif-
icance was set at P ≤ .05. All analyses were performed using Gra-
phPad Prism (GraphPad Prism version 7.00 for Windows,
GraphPad Software, La Jolla, California, www.graphpad.com) and R
statistical software (R version 3.6.0, The R Foundation for Statisti-
cal Computing, Vienna, Austria, https://www.R-project.org/).
The equivalence of PD effects was assessed using log-transformed
results from parts 1 and 3 after first excluding the possibility of carryover
effects because of period or sequence by restricted maximum likelihood
linear mixed model (response ~ mean + drug + period + sequence +
horse) with horse as a random term and all other terms as fixed factors
after testing model assumptions (normal distribution of residuals, constant
variance, and independence). Equivalence of factor level variances was
assessed using the Brown-Forsyth test. The confidence of the null
hypothesis was calculated using the tost function in the equivalence pack-
age in R and expressed as the mean difference of the 2 drugs and the
standard error of these differences for α = 0.05 and ε = 1. Bioequivalence
was demonstrated when the back-transformed 90% confidence interval
for the ratio of the 2 treatment means was contained with the limits 0.8
to 1.25.
3 | RESULTS
All animals completed each phase of the trial, and no adverse effects
attributable to treatment were identified. The granule preparation (NOV)
was well tolerated, with the entire dose consumed within 2 to 5 minutes,
except on days when horses had been sedated for gastroscopy and NGT
placement. No adverse responses were evident after administration of
the registered oral paste (REF) or IV administration of omeprazole.
3.1 | Omeprazole assay performance
The assay met acceptance criteria for performance (Supplementary
Item 3), with intra- and interday precision relative standard deviation
F IGURE 3 Effects of treatment with omeprazole granules (NOV)
at 2 mg/kg (green) and 4 mg/kg (red), compared with results from
untreated horses (baseline, white) on gastric pH at 0800 (24 hours
after treatment) (A), percentage of time pH <4 (B), and mean pH of
gastric fluid (C). Results of Kruskal-Wallis test are shown; differences
in post hoc comparisons were not significant. Data are shown as
median (horizontal line) and quartile (box) with whiskers determined
by the Tukey method
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(RSD) <15% for high (4.5% and 1.7%, respectively) and medium
(10.5% and 0.8%, respectively) concentration standards.23 Accuracy
ranged from 92% to 95% and 92% to 95% of expected values respec-
tively for high and medium concentration standards. Linearity
(r2 > 0.9998) was demonstrated over the calibration curve range from
0 to 5000 ng/mL, and LLoQ and MDL were determined at 0.04 and
0.012 ng/mL, respectively. All other assay performance measures
were within acceptable limits and are presented in Supplementary
Item 5.
3.1.1 | Part 1: Bioavailability study
Plasma concentrations of omeprazole after the single administration
of NOV and REF, and after IV administration, are shown in Figure 1,
and PK parameters are provided in Supplementary Item 4. Consistent
with the higher dose rate administered, Cmax (median, 1032 ng/mL;
range, 576-1766) and AUC0-24 (median, 63.9 μg/mL*min; range,
42.4-152.4) were higher after single dose oral administration of NOV
than REF (282.7 ng/mL; range, 94.8-390.2; and 23.8 μg/mL*min;
range, 8.2-42.3, respectively; both P = .004). The time at which maxi-
mal plasma concentration occurred ranged from 15 to 45 minutes
after administration of NOV, and from 30 to 90 minutes for REF.
There was a difference in Tmax (P = .05) between the 2 treatments.
The terminal slope was calculated based on log-transformed plasma
concentrations from 180 to 480 minutes posttreatment for both oral
products, and from 90 to 360 or 480 minutes after IV treatment. In
comparison to REF, the elimination rate constant (λz) was greater
(P = .04) for NOV and the MRT was less for NOV (P = .01). The
median Fabs of NOV (55%; range, 15-88) was not different to that of
REF (17%; range, 10-77; P = .25). The median relative bioavailability
(FREF/FNOV) was 81% (range, 11-146).
3.1.2 | Part 2: Dose titration
Treatment with NOV at both dose rates was associated with
increased gastric pH in the 24 hours after a single treatment (P < .05)
(Figure 2) and a lower % time pH <4 (P = .04) (Figure 3). There was no
difference in gastric fluid pH between groups treated with 2 or
4 mg/kg omeprazole (Figures 2 and 3).
3.1.3 | Part 3: Comparative clinical and PD study
Gastroscopy and gastric fluid pH
In untreated horses, the mean pH of gastric fluid was <4 for the major-
ity of the 24 hour sampling period (Supplementary Item 5). A transient,
postprandial increase in gastric pH was observed after feeding.
Repeated daily oral administration of NOV (2 mg/kg) and REF
(1 mg/kg) elicited similar effects on pH of gastric fluid in the 24 hours
after treatment on days 1 and 6 (Figure 4), and was associated with
F IGURE 4 Gastric pH in treated
horses on day 1 (top) and day 6 (bottom)
after daily oral administration of a novel
granule formulation (NOV, 2 mg/kg, blue),
and a registered oral paste formulation
(REF, 1 mg/kg, red). A time effect was
observed on both days (P < .001), with
differences in comparison to the initial
sample (<8 am) shown for each treatment
(**P = .005; *P < .05). There was no effect
of treatment (P = .66, day 1; P = .22, day
6) or interaction effect on day 6 (P = .98).
The interaction term (time*treatment) was
significant on day 1 (P = .01); however,
differences in pairwise comparisons were
not present at any time point. Data are
shown as mean and SEM. Values obtained
between 0100 and 0600 hours (shaded
gray) were derived from gastric pH probe
only (pH determination on aspirated
gastric fluid did not occur during his time),
and were excluded from statistical
comparisons. Horses were treated at
0800 hours and fed at 1000 and
1800 hours (arrows)
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increased area under the time-pH curve, increased pH of gastric fluid
24 hours after treatment, and decreased % time pH <4 (Figure 5). Dif-
ferences were not observed between NOV and REF on day 1 (second
daily treatment) or day 6 (seventh daily treatment), and there was no
increase in pH of gastric fluid associated with repeated administration
of either product. Bioequivalence results for PD variables are provided
in Table 1. Bioequivalence was demonstrated for all PD measures with
the exception of % time pH <4.
Repeated daily administration of both NOV and REF was associ-
ated with a lower gastric squamous ulcer score on day 6 when com-
pared with results obtained on day 1 and with results from untreated
horses during the acclimatization phase (Figure 6). There was no dif-
ference in scores between treatments. Squamous lesions most com-
monly involved the lesser curvature. Ulceration of the glandular
mucosa was not assessed.
3.2 | Plasma concentration of omeprazole
Plasma concentrations of omeprazole after single (day 0) and repeated
(day 5) daily administration of NOV and REF are shown in Figure 1, and
PK parameters are provided in Supplementary Item 4. Both oral prod-
ucts demonstrated similar plasma concentrations in parts 1 and 3, char-
acterized by rapid absorption and elimination. The median Cmax on day
5, after repeated daily administration of NOV, was 891.7 ng/mL (range,
88.7-1351) and was greater than that observed for REF (median,
309.1 ng/mL; range, 93.5-384.4, P = .001; Figure 1). There was no dif-
ference in Cmax on day 0. As in part 1, the AUC0-24 was higher after a
single administration of NOV (median, 67.5 μg/mL*min; range,
21.2-84.3) than REF (median, 25.9 μg/mL*min; range, 15.9-36.9), on
day 0 (P = .002). Area under the plasma concentration-time curve was
also higher after repeated daily oral administration of NOV (median,
62.9 μg/mL*min; range, 6-101.7) than REF (median, 24.8 μg/mL*min;
range, 9.6-44.5) on day 5 (P = .002). The time at which maximal plasma
concentration occurred ranged from 15 to 60 minutes after administra-
tion of NOV, and from 30 to 90 minutes for REF. There was no differ-
ence between treatments for Tmax on day 0 or 5.
The terminal slope was calculated based on log-transformed
plasma concentrations from 180 to 480 minutes after treatment for
both oral products. In comparison to NOV, the elimination rate con-
stant (λz) was greater (P = .04) for REF on day 0, but there was no dif-
ference on day 5. There was no difference in MRT on day 0, however
MRT was less for NOV (P = .03) on day 5. The median relative bio-
availability (FREF/FNOV) was 0.19 (range, 0.08-1.71). REF had increased
Cl (P = .002), Vz (P = .009) and elimination half-life (P = .04) when com-
pared with NOV on day 0, but not on day 5. Other PK parameters did
not differ between oral products (Supplementary Item 4).
4 | DISCUSSION
The novel enteric-coated omeprazole in-feed preparation used in this
study was readily consumed by unsedated horses, and our results
F IGURE 5 Effects of treatment with omeprazole granules
(NOV) at 2 mg/kg (blue) and omeprazole paste (REF) at 1 mg/kg
(red), compared with results from untreated horses during
acclimatization and washout phases on gastric pH at 08.0
(24 hours after treatment) (A), percentage of time pH <4 (B), and
area under the time-pH curve (C). Treatment effects were
observed for each variable; results with differing subscripts are
different (P < .05). Data are shown as median (horizontal line) and
quartile (box) with whiskers
WISE ET AL. 627
indicate that it would be a suitable alternative to the reference product,
particularly for horses refractory to the administration of oral paste.
There are several conflicting reports on the impact of feeding on bio-
availability and efficacy of omeprazole,20 and some authors have rec-
ommended that the drug be administered before feeding.13,19 The
consumption of a small amount of food during drug administration did
not adversely affect drug absorption in the current study, as bioavail-
ability was similar for both NOV (administered with a small feed) and
REF (administered without feed). This study did not explore the effects
of larger volumes of feed on the bioavailability of omeprazole.
In the current study, the PK parameters for omeprazole were sim-
ilar to results of previous studies in horses.11,12,16,21,24 As observed in
other species,25,26 absorption after oral administration was rapid, with
Tmax observed within 60 minutes of ingestion for both NOV and REF
products. Plasma concentrations were greater for NOV than REF. This
might reflect the higher dose of NOV administered or the bioavailabil-
ity of the different products. Dose rate, product formulation, and
feeding practices might affect the bioavailability of PO administered
omeprazole.11,19 A higher dose rate was selected for NOV because of
concerns that the granule preparation might be difficult for horses to
consume in entirety and that the small amount of feed administered
concurrently might reduce bioavailability. The bioavailability of NOV
was approximately 50%, and higher than REF (approximately 30%) in
the majority of horses. Oral bioavailability might increase during
repeated administration,27 as inhibition of gastric acid secretion is
likely to decrease drug degradation after oral administration. Although
Fabs after repeated administration was not determined in the current
study, plasma concentrations of omeprazole after daily administration
for 6 days (day 5) in part 3 were not increased relative to day
0, suggesting that bioavailability was similar on both occasions. These
observations suggest that the enteric coating used in both products
successfully protected the drug from degradation in acidic gastric
fluid, but differences in drug absorption attributable to product for-
mulation were not assessed in the current study.
In our study, omeprazole was rapidly eliminated (mean elimina-
tion half-life of approximately 60 minutes) after administration of
both oral preparations, as has been described previously.16,25,26,28,29
Omeprazole might display concentration-dependent elimination
kinetics,27 but differences were not consistently observed between
NOV and REF, despite the disparate dose rates administered and
the greater plasma concentrations observed for NOV. As has been
previously reported after IV administration,28 there was no evidence
of drug accumulation with repeated oral administration in the
current study.
TABLE 1 Results of bioequivalence evaluation of pharmacokinetic (PK) and pharmacodynamic (PD) outcome variables for a commercially
available omeprazole product (REF, 1 mg/kg) and a novel in-feed omeprazole product (NOV, 2 mg/kg)
Parameter Mean difference (log transformed) Standard error of differences P value Outcome
Pharmacokinetic parameters (day 5)
t½ (min)* 0.05 0.12 <.001 Bioequivalent
Tmax (min) 0.1 0.10 <.001 Bioequivalent
Cmax (ng/mL) 1.02 0.26 .53 NOV > REF
a
AUC0-t (μg/mL*min) 0.78 0.28 .20 NOV > REFa
AUC0-∞ (μg/mL*min) 0.78 0.28 .19 NOV > REFa
AUMC0-∞ (μg/mL*min2) 0.61 0.25 .06 NOV > REFa
MRT0-∞ (h) 0.17 0.08 <.001 Bioequivalent
Vz (L/kg) 0.13 0.37 .01 Bioequivalent
Cl (mL/kg/min) 0.08 0.28 .001 Bioequivalent
Pharmacodynamic parameters (day 1)
AUCpH-time 0.08 0.08 <.001 Bioequivalent
Initial pH (preTx) 0.34 0.16 .001 Bioequivalent
Mean pH 0.03 0.08 <.001 Bioequivalent
% time pH <4 (24 h) 0.2 0.52 .07 NOV > REF
% time pH <4 (12 h) 0.81 0.55 .35 REF > NOV
Pharmacodynamic parameters (day 6)
AUCpH-time 0.01 0.08 <.001 Bioequivalent
Initial pH (preTx)b 0.02 0.17 <.001 Bioequivalent
Mean pHb 0.02 0.07 <.001 Bioequivalent
% time pH <4 (24 h) 0.07 0.43 .01 Bioequivalent
% time pH <4 (12 h) 0.45 0.26 .06 REF > NOV
aConsistent with higher dose rate for NOV.
bSignificant effect associated with phase.
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Despite differences in dose rate, both products demonstrated
similar beneficial effects on gastric pH and healing of gastric squa-
mous ulcers. The feeding protocol used in the current study was iden-
tical to that used previously by this group,20 and was associated with
a low pH in the acclimatization and washout periods, such that pH
was <4 for approximately 60% of the 24 hour period in untreated
horses. Despite rapid Cl of plasma omeprazole concentrations, oral
omeprazole treatment was associated with a protracted suppression
of gastric acid secretion. We were unable to demonstrate a dose-
response association after administration of a single oral dose of NOV
in part 2. This might indicate that the observed PD responses were
close to maximal. Similarly, although repeated administration of omep-
razole has been associated with increased suppression of gastric acid
secretion,28,27 results on days 1 and 6 of the current study were not
different. The effects of omeprazole administration on squamous ulcer
score were assessed after repeated daily administration in part 3:
despite the short study period, beneficial effects on gastric squamous
ulcer score were observed after the repeated administration of both
NOV and REF. The PD data support once daily administration of oral
omeprazole to horses, as measures of gastric acid secretion, including
AUC0-24, mean pH, initial pH and percent time pH <4, demonstrated
appropriate inhibition after once daily administration. There was no
evidence of drug accumulation at this dose interval. In the current
study, PD effects were further assessed by tests of bioequivalence to
reduce chances of type 2 error. Using this approach, we were able to
demonstrate that the majority of PD parameters were the same for
NOV and REF.
The pH of gastric secretion has been determined previously by
collection of samples from gastric cannulas,13,30,31 aspiration of gastric
fluid via endoscopy or nasogastric intubation, or indwelling nasogas-
tric pH probes.20,32,33 In the current study, the pH of gastric fluid was
determined by both continuous measurement using indwelling anti-
mony probes, and intermittent aspiration of gastric content, as
described previously.20 This approach avoids surgical creation of per-
manent access to the gastric lumen, but necessitates sedation to per-
mit NGT placement. As sedation might have affected gastrointestinal
motility and time to consume NOV, PK and PD studies were not per-
formed concurrently, and this precluded direct comparison of plasma
drug concentration and physiological effect. As both methods used in
this study are subject to false readings or missing data, for example,
because of partitioning of gastric content, probe breakage, reflux of
duodenal content, or aspiration of saliva, the simultaneous use of both
methods allowed comparison of results and minimized missing data
points. In all cases, where values were available from both probe and
aspirated fluid, the lower value was used, as has been
recommended,34 to ensure that treatment effects were not over-
estimated. As gastric fluid was not aspirated after 00.00 or before
07.00 hours, pH results between 01.00 and 06.00 hours (inclusive)
were obtained only from gastric probes and, as such, were not sub-
stantiated as was possible for other data points.
A further limitation of the current study is that treatment effects
of omeprazole on squamous mucosal ulcer scores were observed in a
small sample of Thoroughbred and Standardbred mares with mild
squamous ulceration of questionable clinical importance. Squamous
ulceration scores were assigned by a single investigator blinded to
treatment at the time of probe placement and removal. Glandular
ulceration scores were not assessed because probe placement, feed
retention, or a combination of both, after omeprazole treatment pre-
cluded full assessment of the pyloric antrum in many cases, and
because oral omeprazole treatment of glandular ulceration is not as
effective as for squamous lesions.35 Horses with more severe, sponta-
neous gastric disease were not utilized, and a negative control group
was not included in the current study. Although an effect on gastric
squamous ulcer score was observed, the current study was not
designed to assess clinical efficacy and a larger, controlled study of
horses with spontaneous disease is required to better characterize the
effect of treatment on ulcer healing.
5 | CONCLUSION
Administration of both omeprazole products resulted in increased gas-
tric pH relative to untreated horses. Similarly, mean pH was increased
and the percent of time that gastric pH <4 was decreased by treat-
ment, and bioequivalence of both products was demonstrated based
on these 2 parameters, indicating that PD effects were the same
F IGURE 6 Gastric squamous ulcer scores during treatment.
Analysis of variance on ranks (Friedman test) demonstrated a
treatment effect, with scores on day 6 lower than on day 1 after
treatment with both granules (NOV, 2 mg/kg, P = .001) and paste
(REF, 1 mg/kg, P = .02) formulations. Post hoc testing (Dunn's
method) demonstrated a reduction in gastric squamous ulcer score on
day 6 in comparison with values determined in week
1 (acclimatization, **) after treatment with both NOV (P = .004) and
REF (P = .007). Results are shown as median (horizontal line),
interquartile range (box) and range (whiskers), with all data points
shown
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regardless of dose rate for both products. The findings of this study
confirm that plasma concentrations of omeprazole and omeprazole
dose do not predict drug PD.
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